Quarterly report pursuant to Section 13 or 15(d)

Research and License Agreements (Details Narrative)

v3.20.2
Research and License Agreements (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 5 Months Ended 6 Months Ended
Nov. 30, 2020
Jun. 30, 2020
May 31, 2020
Mar. 31, 2019
Dec. 31, 2018
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2020
Sep. 30, 2019
Aug. 30, 2020
Sep. 30, 2020
Sep. 30, 2019
Research and development               $ 870,876 $ 200,217   $ 1,468,221 $ 347,858
Product sales               837,714 1,201,127   1,741,781 2,711,962
Net Product Sales-Related Party [Member]                        
Product sales               476,496 634,262   896,140 1,584,446
Collaborative Research Revenue [Member]                        
Product sales               40,000   40,000
University of Louisville Research Foundation [Member] | Minimum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                        
Shortfall payments                     5,000  
University of Louisville Research Foundation [Member] | Maximum [Member] | Royalties and Non-Royalty Sublicensee Income [Member]                        
Shortfall payments                     50,000  
License and Sponsored Research Agreements [Member]                        
Research and development                     2,000 126,000
Patents cost                     164,000 66,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]                        
Payment of convertible promissory note           $ 50,000 $ 50,000          
Reimbursement of research expenses           805,000 805,000          
Reimbursement patent cost           $ 200,000 $ 200,000          
Agreement term payment, description           In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter) In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter)          
Licensed product sales, revenue           $ 500,000,000 $ 500,000,000          
Milestone payment for marketing expenses           500,000 500,000          
Research and development               50,000 39,000   112,000 14,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Intellectual Property [Member]                        
Research and development               490,000     678,000  
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]                        
Regulatory marketing approval, expenses       $ 5,000,000   500,000 500,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]                        
Milestone payment       50,000   100,000 100,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]                        
Milestone payment       100,000   200,000 200,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]                        
Milestone payment       150,000   350,000 350,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                        
Milestone payment           100,000 100,000          
Shortfall payments           10,000 10,000          
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                        
Milestone payment           5,000,000 5,000,000          
Shortfall payments           $ 50,000 $ 50,000          
Sponsored Research and License Agreement [Member]                        
Research and development               0 93,000      
Patents cost               17,000 $ 6,000      
Sponsored research expense                     139,000 $ 20,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]                        
Reimbursement patent cost       $ 112,000                
Agreement term payment, description       In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter),                
Regulatory marketing approval, expenses       $ 300,000                
Licensed product sales, revenue       500,000,000                
Research and development       693,000                
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                        
Milestone payment       50,000                
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                        
Milestone payment       5,000,000                
License Agreement [Member] | University of Louisville Research Foundation [Member]                        
Upfront license fee   $ 24,000                    
ULRF license agreement description   In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales.                    
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]                        
Upfront license fee       20,000                
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]                        
Research and development   $ 250,000                    
Upfront license fee       $ 100,000                
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] | Subsequent Event [Member]                        
Research and development $ 430,000                      
License Agreement [Member] | Advanced Cancer Therapeutics [Member]                        
Licensed product sales, revenue         $ 3,000,000              
Research and development               $ 100,000     $ 110,000  
Proceeds from convertible promissory note         $ 25,000              
Agreement description         Royalties, on net sales associated with the commercialization of ACT-GRO-777/AS1411, of 2% (only if patent-covered and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000), until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $100,000 for the Company raising a cumulative total of $2,000,000 in new equity financing after the date of the ACT license agreement, $100,000 upon any first AS1411-based licensed product receiving the CE Mark or similar FDA status, and $500,000 upon cumulative worldwide AS1411-based licensed product net sales reaching $3,000,000              
Milestone payment     $ 100,000   $ 100,000              
Cumulative amount     $ 2,000,000   2,000,000              
Purchased drug compounds                   $ 10,000    
Rectification of additionaldrug compounds                   50,000    
License Agreement [Member] | Advanced Cancer Therapeutics [Member] | CE Mark [Member]                        
Milestone payment         100,000              
Cumulative amount         $ 500,000              
License Agreement [Member] | Advanced Cancer Therapeutics [Member] | Investigational New Drug [Member]                        
Rectification of additionaldrug compounds                   $ 100,000